No due process

Regulators and public health bodies allowed their wards to stand into danger

The Kansas indictment of Comirnaty, summarised in our previous post, provides the basis for a few considerations.

First, none of what the Kansas Attorney General (AG) Kris Kobach said was unknown in December 2020 or was not easily foreseen.

No trials had been conducted in pregnant women, and pregnancy was an exclusion criterion for participating in the pivotal trial. Pfizer’s own PK study indicated a high concentration of lipid nanoparticles (LNPs) in rats’ ovaries. All regulators were aware of this, as the thin PK studies were part of the regulatory submission.

Exploring regulatory data sets of the Comirnaty vaccine - 9a

Given this widespread scatter of the LNPs and given their property of evading immunity, each system in the human body was a potential target and, therefore, open to potential harm by a scantily tested technology (we are being generous here).

The protective effect of Comirnaty is untested today. The clinical study report of the pivotal trial does not provide evidence that it can affect viral load and create viral “dead ends,” as Dr…